RepliCel Life Sciences (RepliCel Life Sciences) EV-to-EBIT : -46.23 (As of May. 17, 2024)

View and export this data going back to 2004. Start your Free Trial

What is RepliCel Life Sciences EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, RepliCel Life Sciences's Enterprise Value is $2.64 Mil. RepliCel Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.06 Mil. Therefore, RepliCel Life Sciences's EV-to-EBIT for today is -46.23.

The historical rank and industry rank for RepliCel Life Sciences's EV-to-EBIT or its related term are showing as below:

REPCF' s EV-to-EBIT Range Over the Past 10 Years
Min: -340.86 Med: -2.5 Max: 109.22
Current: -52.71

During the past 13 years, the highest EV-to-EBIT of RepliCel Life Sciences was 109.22. The lowest was -340.86. And the median was -2.50.

REPCF's EV-to-EBIT is ranked worse than
100% of 431 companies
in the Biotechnology industry
Industry Median: 10 vs REPCF: -52.71

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. RepliCel Life Sciences's Enterprise Value for the quarter that ended in Sep. 2023 was $5.53 Mil. RepliCel Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.06 Mil. RepliCel Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -1.03%.

RepliCel Life Sciences EV-to-EBIT Historical Data

The historical data trend for RepliCel Life Sciences's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RepliCel Life Sciences EV-to-EBIT Chart

RepliCel Life Sciences Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-EBIT

Get a 7-Day Free Trial

-2.78

-2.43

-4.90

-1.93

-4.96

RepliCel Life Sciences Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-EBIT	Get a 7-Day Free Trial															-1.05	-4.96	-10.20	-30.98	-114.84

Competitive Comparison of RepliCel Life Sciences's EV-to-EBIT

For the Biotechnology subindustry, RepliCel Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RepliCel Life Sciences's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RepliCel Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where RepliCel Life Sciences's EV-to-EBIT falls into.

RepliCel Life Sciences EV-to-EBIT Calculation

RepliCel Life Sciences's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2.635	/	-0.057
	=	-46.23

RepliCel Life Sciences's current Enterprise Value is $2.64 Mil.
RepliCel Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

RepliCel Life Sciences (OTCPK:REPCF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

RepliCel Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2023 )	=	EBIT	/	Enterprise Value (Q: Sep. 2023 )
	=	-0.057	/	5.531136
	=	-1.03 %

RepliCel Life Sciences's Enterprise Value for the quarter that ended in Sep. 2023 was $5.53 Mil.
RepliCel Life Sciences's EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.

RepliCel Life Sciences EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of RepliCel Life Sciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

RepliCel Life Sciences (RepliCel Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RepliCel Life Sciences Inc (OTCPK:REPCF) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

P6P2:Germany P6P2:Germany RP:Canada

Address

570 Granville Street, Suite 900, Vancouver, BC, CAN, V6C 3P1

Website

https://www.replicel.com

RepliCel Life Sciences Inc is a Canadian regenerative medicine company. It focuses on developing autologous cell therapies that treat functional cellular deficits. The company addresses various diseases such as chronic tendon injuries, androgenetic alopecia, and skin aging. Its development program of the company is based on distinct technology that utilizes cells isolated from a patient's healthy hair follicles. Also, the company develops a programmable cell injector device designed for dermal injections of cells, dermal filler products, and a variety of other products injected through the skin. The treatments delivered by the company use autologous cell therapy which is developed for the treatment of androgenetic alopecia. The revenue is generated from Licensing fees.